Newsroom | 68184 results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. “This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr...

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2025. Financial Highlights Three Months Ended December 31,     Year Ended December 31,   (In millions, except per share amounts) 2025     2024     2025     2024   GAAP                       Revenue $ 258.3     $ 238.1     $ 980.6     $ 949.2   Operating Inc...

米ニュージャージー州ジャージーシティ--(BUSINESS WIRE)--（ビジネスワイヤ） -- より健康な毎日のために効果的な医薬品とソリューションの提供を使命に掲げるグローバルヘルスケア企業のオルガノン（NYSE：OGN）は本日、セベラ・ファーマシューティカルズのホルモンフリー銅製子宮内避妊具（IUD）であるMIUDELLAについて、世界における権利を独占的にライセンスする契約を締結したと発表しました。本取引の成立は、ハート・スコット・ロディーノ反トラスト改正法（HSR法）に基づく審査、およびMIUDELLAの代替サプライチェーンに関わる事業体の承認を含む米国食品医薬品局（FDA）による承認、その他一定の条件を満たすことを前提としています。 過去40年で米国において承認された初のホルモンフリー銅製IUDであるMIUDELLAはオルガノンの商業展開力と補完関係にあり、女性の多様なリプロダクティブ・ヘルス（生殖に関する健康）ニーズに応える製品ポートフォリオの構築に向けたオルガノンの取り組みをさらに推進します。MIUDELLAは2025年2月24日にFDAより承認を取得しており、妊娠...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced interim data from its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-201 in people living with amyotrophic lateral sclerosis (ALS). Results from this study demonstrated QRL-201 had an effect on disease pro...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference...

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the “Company”) (Nasdaq: CCRN) announced today that it is scheduled to participate in two upcoming conferences: The Truist Securities Virtual Human Capital Conference taking place March 12-13, 2026, with one-on-one investor meetings on Thursday, March 12. The Oppenheimer 36th Annual Healthcare MedTech & Services Conference taking place March 16-19, 2026, with one-on-one investor meetings on Tuesday, March 17. In attendance an...

NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) today announced its financial results for the quarter ended December 31, 2025 and provided full year 2026 financial guidance, which can be found at the Quarterly Reports section of DHC's website at https://www.dhcreit.com/investors/financial-information/quarterly/default.aspx. A conference call to discuss DHC's fourth quarter 2025 financial results will be held on Tuesday, February 24, 2026 at 10:00 a.m. Eastern Time. Th...

FRISCO, Texas--(BUSINESS WIRE)--Addus HomeCare Corporation (NASDAQ: ADUS), a provider of home care services, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Highlights: Net Service Revenues Increase 25.6% to $373.1 Million Net Income of $29.8 Million, or $1.61 per Diluted Share Adjusted Net Income per Diluted Share Increases 28.3% year-over-year to $1.77 Adjusted EBITDA Increases 33.3% year-over-year to $50.3 Million Cash Flow f...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR S...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon (NYSE: OGN), ein globales Gesundheitsunternehmen mit der Mission, wirkungsvolle Medikamente und Lösungen für einen gesünderen Alltag anzubieten, gab heute bekannt, dass es eine Vereinbarung über die exklusive Lizenzierung der weltweiten Rechte an MIUDELLA, dem hormonfreien Kupfer-Intrauterinpessar (IUP) von Sebela Pharmaceuticals, geschlossen hat. Die Wirksamkeit dieser Transaktion unterliegt der Prüfung gemäß dem Hart-Scott-Rodino Antitrust Imp...